Skip to content

The use of testosterone in brain dead patients who are candidates for organ donation in order to maintain and stabilize blood pressure

The effects of testosterone injection in maintaining the stability of blood pressure and hemodynamic parameters of brain dead patients who are candidates for organ donation

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130304012695N17
Enrollment
80
Registered
2023-05-13
Start date
2023-05-22
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain dead. Other specified disorders of central nervous system

Interventions

Intervention 1: Intervention group: 100 mg of testosterone enanthate drug (manufactured by Caspian Tamin Company) was prepared by nurse of the intensive care department according to the grouping of th

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Brain dead patients aged 18-60 years are candidates for organ donation

Exclusion criteria

Exclusion criteria: Patients who have high blood pressure and do not need inotropes Hemodynamically unstable patients who will undergo organ donation surgery in less than 6 hours

Design outcomes

Primary

MeasureTime frame
Dosage of noradrenaline. Timepoint: At the beginning of the patient's entry into the study and 8 hours after drug injection. Method of measurement: milliliters per hour.;Peripheral vascular resistance. Timepoint: At the beginning of the patient's entry into the study and 8 hours after drug injection. Method of measurement: By Ultrasonic Cardiac Output Monitor.

Secondary

MeasureTime frame
Cardiac output. Timepoint: At the beginning of the patient's entry into the study and 8 hours after drug injection. Method of measurement: By Ultrasonic Cardiac Output Monitor.;Cardiac Index. Timepoint: At the beginning of the patient's entry into the study and 8 hours after drug injection. Method of measurement: By Ultrasonic Cardiac Output Monitor.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Khajavi

Tehran University of Medical Sciences

KHAGAVIM@TUMS.AC.IR+98 21 6312 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026